Clinical trial · Observational
Immunotherapy in Upper Tract Urothelial Carcinoma
Carcinomes urothéliaux Des Voies excrétrices supérieures traitées en Vie réelle Par immunothérapie (VESUVIO) : étude rétrospective Nationale
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Upper-tract urothelial carcinoma (UTUC) is a rare tumor. Standard treatment of localized disease is most often radical nephroureterectomy. In advanced/metastatic disease, treatments follow the standards for urothelial carcinoma including platinum-based chemotherapy and anti-PD(L)1 (Programmed death (ligand) 1) immunotherapy, with no regard as to the primary disease site (bladder or upper tract). Given the rarity of UTUC, efficacy data in the UTUC subgroup of advanced urothelial carcinoma is scarce. UTUC show distinct pahological and molecular features, including higher prevalence of microsatellite instability and of abnormalities in the FGFR (fibroblast growth factor receptors) gene family. These specific features may impact outcomes of immunotherapy in advanced/metastatic UTUC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Urothelial Carcinoma | Urothelial Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Evaluation of anti-PD-(L)1 immunotherapy efficacy | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with advanced/metastatic UTUC treated with second-line anti-PD-(L)1 immunotherapy
- interventionNames
- Other: Evaluation of anti-PD-(L)1 immunotherapy efficacy
Primary outcomes (1)
- measure
- Overall survival on anti-PD-(L)1 immunotherapy
- timeFrame
- 2 years after immunotherapy initiation
Secondary outcomes (9)
- measure
- Best Objective Radiologic Response
- timeFrame
- Up to 7 years maximum
- description
- Evaluated by RECIST v1.1 The Response Evaluation Criteria in Solid Tumors (RECIST) is a standard system to measure how cancer responds to different treatments.It permits to evaluate the response according to the evolution of the lesions.
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18 and more * Diagnosis of urothelial carcinoma (with or without variant histology) * Advanced/metastatic disease not amenable to local treatment with curative intent * Treatment with an anti-PD-(L)1 monoclonal antibody initiated between 2016 and 2022 Exclusion Criteria: * Patient's opposition to this research * Urothelial carcinoma of bladder or urethral primary site * Non-urothelial tumor * Maintenance immunotherapy initiated without disease progression
References
Publications (0)
Data not yet available